Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 4/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928721 | 0.78 | TDP1 (0.51) | DUTL3MBTL1GAAMAPTTDP1 | |
| SCHEMBL13315401 | 0.72 | HDAC1 (0.47) | DUTMAPTPPARA | |
| SCHEMBL4008271 | 0.72 | HDAC1 (0.47) | DUTMAPTPPARA | |
| SCHEMBL4008275 | 0.72 | HDAC1 (0.47) | DUTMAPTPPARA | |
| SCHEMBL9433444 | 0.72 | L3MBTL1 (0.46) | L3MBTL1GAAMAPTTDP1 | |
| SCHEMBL4156053 | 0.72 | SLC6A4 (0.37) | DUTATMTDP1 | |
| SCHEMBL9049258 | 0.72 | GAA (0.39) | L3MBTL1GAAMAPTATM | |
| SCHEMBL25893279 | 0.71 | TDP1 (0.65) | L3MBTL1TDP1 | |
| SCHEMBL21174515 | 0.70 | DUT (0.39) | DUTMAPTPPARA | |
| SCHEMBL2252126 | 0.69 | IDO1 (0.53) | DUTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-9499503-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9102639-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150210658-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-8623895-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120270803-A1 | Mitotic Kinesin Inhibitors and Methods of Use Thereof | ARRAY BIOPHARMA, INC. | 2012-10-25 | — | — | US | disclosed |
| US-8236825-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7449486-B2 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | ARRAY BIOPHARMA, INC. | 2008-07-31 | — | — | US | disclosed |
| EP-1809280-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006044825-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210658-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | DUT 382/4885L3MBTL1 3042/4885GAA 426/4885 |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | KIF5B, KIF2C, KIFC1 | DUT 560/4885L3MBTL1 4125/4885GAA 1602/4885 |
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | DUT 199/4885L3MBTL1 2309/4885GAA 1012/4885 |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | KIF5B, KIF2C, KIFC1 | DUT 391/4885L3MBTL1 3641/4885GAA 1625/4885 |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF18B, KIF18A | DUT 199/4885L3MBTL1 2309/4885GAA 1012/4885 |
| US-20120270803-A1 | Mitotic Kinesin Inhibitors and Methods of Use Thereof | KIF5B, KIF2C, KIFC1 | DUT 382/4885L3MBTL1 3042/4885GAA 426/4885 |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | DUT 199/4885L3MBTL1 2309/4885GAA 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.